FDA approves Yeztugo HIV prevention injection showing 96% efficacy in clinical trials, but $14,000 cost creates significant access barriers for patients.

The drug, lamivudine, appears to improve vision that’s being threatened by diabetic macular edema (DME), an eye condition in ...

The US Food and Drug Administration has approved lenacapavir (Yeztugo), the first twice-yearly injectable HIV-1 prevention ...

Gilead Sciences’ Yeztugo receives nod; the first and only US FDA-approved HIV prevention option offering 6 months of protection: Foster City, California Friday, June 20, 2025, 1 ...

New commitments at Bali forum drive momentum to save hundreds of thousands of girls and women from cancer.Bali, Indonesia, 19 June 2025 - Governments, donors, multilateral institutions, the private ...

Dr. Sanjib Kumar Sharma serves as the Acting Vice-Chancellor as well as Rector at BP Koirala Institute of Health Sciences (BPKIHS), Dharan, Nepal.

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...

University of Michigan researchers have uncovered new details of the process that HIV uses to hijack cells' transportation ...

FDA Approves Yeztugo as First Twice-Yearly Injectable HIV Prevention Option in the U.S. Clinical Trials Show Near-Perfect ...

“This is a historic day in the decades-long fight against HIV,” Gilead CEO Daniel O’Day said in the company’s announcement.

University of Michigan researchers have uncovered new details of the process that HIV uses to hijack cells’ transportation ...

The breakthrough double injection won’t be cheap in the US, although scientists argue it could (and should) be.